Immunotherapies that target programmed death 1/programmed death ligand 1 (PD1/PD-L1) have become the standard treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) [1, 2]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.